718 related articles for article (PubMed ID: 32122376)
21. PARP Inhibition and Beyond in BRCA-Associated Breast Cancer in Women: A State-Of-The-Art Summary of Preclinical Research on Risk Reduction and Clinical Benefits.
Pauwels EKJ; Bourguignon MH
Med Princ Pract; 2022; 31(4):303-312. PubMed ID: 35636395
[TBL] [Abstract][Full Text] [Related]
22. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
Noordermeer SM; van Attikum H
Trends Cell Biol; 2019 Oct; 29(10):820-834. PubMed ID: 31421928
[TBL] [Abstract][Full Text] [Related]
23. Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
Lohse I; Kumareswaran R; Cao P; Pitcher B; Gallinger S; Bristow RG; Hedley DW
PLoS One; 2016; 11(12):e0167272. PubMed ID: 28033382
[TBL] [Abstract][Full Text] [Related]
24. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
[TBL] [Abstract][Full Text] [Related]
25. A review on mechanisms of resistance to PARP inhibitors.
Desai C; Pathak A; Limaye S; Maniar V; Joshi A
Indian J Cancer; 2022 Mar; 59(Supplement):S119-S129. PubMed ID: 35343196
[TBL] [Abstract][Full Text] [Related]
26. Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors.
Cheng X; Zhang B; Guo F; Wu H; Jin X
Mol Oncol; 2022 Apr; 16(7):1591-1607. PubMed ID: 34854226
[TBL] [Abstract][Full Text] [Related]
27. Molecular pathways: targeting PARP in cancer treatment.
Do K; Chen AP
Clin Cancer Res; 2013 Mar; 19(5):977-84. PubMed ID: 23269547
[TBL] [Abstract][Full Text] [Related]
28. PARP inhibitors in ovarian cancer.
Ledermann JA
Ann Oncol; 2016 Apr; 27 Suppl 1():i40-i44. PubMed ID: 27141070
[TBL] [Abstract][Full Text] [Related]
29. PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials.
Kamel D; Gray C; Walia JS; Kumar V
Curr Drug Targets; 2018; 19(1):21-37. PubMed ID: 28699513
[TBL] [Abstract][Full Text] [Related]
30. BRCA mutations in pancreatic cancer and progress in their targeting.
Alkassis S; Yazdanpanah O; Philip PA
Expert Opin Ther Targets; 2021 Jul; 25(7):547-557. PubMed ID: 34289788
[No Abstract] [Full Text] [Related]
31. mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance.
Bu C; Zhao L; Wang L; Yu Z; Zhou J
Oncol Res; 2023; 31(4):495-503. PubMed ID: 37415733
[TBL] [Abstract][Full Text] [Related]
32. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
33. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
34. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
Tewari KS; Eskander RN; Monk BJ
Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965
[TBL] [Abstract][Full Text] [Related]
35. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Gunderson CC; Moore KN
Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
37. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.
Boussios S; Karihtala P; Moschetta M; Abson C; Karathanasi A; Zakynthinakis-Kyriakou N; Ryan JE; Sheriff M; Rassy E; Pavlidis N
Invest New Drugs; 2020 Feb; 38(1):181-193. PubMed ID: 31650446
[TBL] [Abstract][Full Text] [Related]
38. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
[TBL] [Abstract][Full Text] [Related]
39. The DNA damaging revolution.
Cetin B; Wabl CA; Gumusay O
Crit Rev Oncol Hematol; 2020 Dec; 156():103117. PubMed ID: 33059228
[TBL] [Abstract][Full Text] [Related]
40. Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials.
Nambiar DK; Mishra D; Singh RP
Oncol Res; 2023; 31(4):405-421. PubMed ID: 37415740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
